Title: Comparison study of telmisartan/hydrochlorothiazide tablets and losartan potassium/hydrochlorothiazide tablets on antihypertensive efficacy and reversing vascular endothelial dysfunction
Abstract: Objective To compare the different effects on antihypertensive efficacy and reversing vascular endothelial dysfunction(VED) of hypertensive patients by Telmisartan/Hydrochlorothiazide or Losartan Potassium/Hydrochlorothiazide tablets.Methods 61 hypertensive patients were randomly divided into Telmisartan/Hydrochlorothiazide group and Losartan Potassium/Hydrochlorothiazide group and received the treatment with Telmisartan/Hydrochlorothiazide tablets or Losartan Potassium/Hydrochlorothiazide tablets 1 tablet per day for 8 weeks.The rates of under control were calculated.Serum hepatocyte growth factor(HGF),serum nitric oxide(NO) and plasma endothelin(ET) were measured before and after treatment.Results (1)After 8-week treatment SBP and DBP in either group were significally decreased(P0.01),but SBP,DBP and the rates of under control were not different between two groups(P0.05).(2)The levels of serum HGF and plasma ET were higher in hypertensive patients,and the levels of serum NO were lower than those in normal(P0.01).The levels of serum HGF and plasma ET after treatment were lower group and the levels of serum NO were higher than those before treatment(P0.01),the levels of serum △HGF and △NO after treatment were not different between two group(P0.05),but the levels of plasma △ET and △ET/△NO ratio were significally different(P0.01).Conclusion (1)After 8-week treatment two drugs have the same antihypertensive efficacy.(2)Both drugs have some effects on reversing VED of hypertensive patients,but Telmisartan/hydrochlorothiazide tablets is possiblely better than Losartan potassium/hydrochlorothiazide tablets in reversing VED.
Publication Year: 2009
Publication Date: 2009-01-01
Language: en
Type: article
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot